
    
      A randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over,
      single-dose phase IIa study to investigate the bronchodilatory and systemic effects of 4
      different doses of inhaled AZD8683 in patients with Chronic Obstructive Pulmonary Disease
      (COPD).
    
  